| Antidepressants | Seizure Incidence (%) |
| TCAs and tetracyclic antidepressants | |
|---|---|
| Amitriptyline | <0.1-0.3 |
| Amoxapine | 24.5-36.4 |
| Clomipramine | 0.7-3.0 |
| Desipramine | <0.1 |
| Doxepin | <0.1 |
| Imipramine | <0.1-0.9 |
| Maprotiline | 0.4-15.6 |
| Nortriptyline | <0.1 |
| Protriptyline | <0.1 |
| SSRI and SNRI | |
| Citalopram | <0.1 |
| Fluoxetine | <0.1-0.2 |
| Fluvoxamine | <0.2 |
| Paroxetine | <0.1 |
| Sertraline | <0.1 |
| Venlafaxine | <0.26 |
| Other antidepressants | |
| Bupropion | 0.6-1.0 |
| >450 mg/day | 0.6-2.19 |
| SR 400 mg/day | 0.4 |
| SR 300 mg/day | 0.1 |
| Mirtazapine | <0.1 |
| Nefazodone | NA |
| Trazodone | <0.1 |
TCAs = tricyclic antidepressants
SNRI = serotonin-norepinephrine reuptake inhibitor
SSRI = selective serotonin reuptake inhibitor
SR = sustained-release formula
NA = limited information
Adapted from: Barry JJ and Huynh N. Psychotropic drug use in patients with epilepsy and developmental disabilities. In: Devinsky O and Westbrook LE, eds. Epilepsy and Developmental Disabilities. Boston: Butterworth-Heinemann; 2001;205-217.
With permission from Elsevier (www.elsevier.com).
